India's Natco Pharma Applies For Nation's First Compulsory License, Bayer's Nexavar
This article was originally published in PharmAsia News
Natco Pharma of India has filed the nation's first request for a compulsory license to be allowed to market a generic of a drug still under patent protection, this one by Germany's Bayer
You may also be interested in...
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.
Plaintiffs against the prestige, “clinical” skin-care company are targeting anti-aging claims on its Rose Stem Cell Bio-Repair line and statements about hyaluronic acid’s ultra-moisturizing capabilities, used to market its Water Drench range. PTR faces false advertising class actions in California and New York federal courts, and the former case appears to be headed for trial.